These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 28487578)
1. 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Jun JEJ; Kinkade A; Tung ACH; Tejani AM Can J Hosp Pharm; 2017; 70(2):113-119. PubMed ID: 28487578 [TBL] [Abstract][Full Text] [Related]
2. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908 [TBL] [Abstract][Full Text] [Related]
3. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710 [TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. Li Y; Ma J; Qin XH; Hu CY Transl Androl Urol; 2022 Mar; 11(3):313-324. PubMed ID: 35402192 [TBL] [Abstract][Full Text] [Related]
5. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride. Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700 [TBL] [Abstract][Full Text] [Related]
6. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241 [TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. Zhou Z; Cui Y; Wu J; Ding R; Cai T; Gao Z BMC Urol; 2019 Mar; 19(1):17. PubMed ID: 30871552 [TBL] [Abstract][Full Text] [Related]
8. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia. Dolder CR Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. Novara G; Giannarini G; Alcaraz A; Cózar-Olmo JM; Descazeaud A; Montorsi F; Ficarra V Eur Urol Focus; 2016 Dec; 2(5):553-561. PubMed ID: 28723522 [TBL] [Abstract][Full Text] [Related]
10. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. Logan YT; Belgeri MT Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387 [TBL] [Abstract][Full Text] [Related]
11. A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia. Zong HT; Peng XX; Yang CC; Zhang Y Asian J Androl; 2011 Nov; 13(6):812-8. PubMed ID: 21892196 [TBL] [Abstract][Full Text] [Related]
12. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. Park T; Choi JY World J Urol; 2014 Aug; 32(4):1093-105. PubMed ID: 24500194 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials. Zhou Z; Cui Y; Wu J; Jin H Exp Ther Med; 2020 Aug; 20(2):1566-1574. PubMed ID: 32742388 [TBL] [Abstract][Full Text] [Related]
15. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065 [TBL] [Abstract][Full Text] [Related]
16. The role of combination medical therapy in benign prostatic hyperplasia. Greco KA; McVary KT Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123 [TBL] [Abstract][Full Text] [Related]
17. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695 [TBL] [Abstract][Full Text] [Related]
18. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Naslund MJ; Miner M Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044 [TBL] [Abstract][Full Text] [Related]
19. A review of combination therapy in patients with benign prostatic hyperplasia. McVary KT Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature. Busetto GM; Del Giudice F; D'Agostino D; Romagnoli D; Minervini A; Rocco B; Antonelli A; Celia A; Schiavina R; Cindolo L; Chung BI; Kim JH; Maggi M; Sciarra A; De Berardinis E; Porreca A Arch Ital Urol Androl; 2020 Jan; 91(4):205-210. PubMed ID: 31937082 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]